Clinical Trials

255 enrolled

Endometrial Neoplasms

NCT05256225 2026-06-03

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

360 enrolled

Neoplasms, Endometrial Neoplasms

NCT06952504 2026-06-03

TroFuse-033

1,123 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT04269200 2026-06-01

DUO-E

805 enrolled 18 charts 1 FDA

Endometrial Neoplasms

NCT06989112 2026-05-06

DE-01

600 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT05173987 2026-05-05

KEYNOTE-C93

280 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT03884101 2026-02-02

LEAP-001

Phase 3 Completed

842 enrolled 25 charts

Endometrial Neoplasms

NCT04865289 2025-12-02

LEAP-001

Phase 3 Completed

130 enrolled 24 charts

Endometrial Neoplasms

NCT03603184 2025-05-09

AtTEnd

Phase 3 Completed

549 enrolled

Neoplasms, Endometrial Neoplasms

NCT01820858 2024-04-02

EC-01

300 enrolled

Endometrial Neoplasms

NCT02584478 2023-11-08

AL3818

Phase 3 Unknown

294 enrolled

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00411138 2023-10-11

PORTEC-3

Phase 3 Unknown

670 enrolled